The serotonin transporter (5-HTT) regulates serotonergic neurotransmission via clearance of extracellular serotonin. Abnormalities in 5-HTT expression or function are found in mood and anxiety disorders, and the 5-HTT is a major target for antidepressants and anxiolytics. The 5-HTT is further implicated in the pathophysiology of these disorders by evidence that genetic variation in the promoter region of the HTT (SLC6A4) is associated with individual differences in anxiety and neural responses to fear. To further evaluate the role of the 5-HTT in anxiety, we employed a mouse model in which the 5-HTT gene (htt) was constitutively inactivated. 5-HTT À/À mice were characterized for anxiety-related behaviors using a battery of tests (elevated plus maze, light2dark exploration test, emergence test, and open field test). Male and female 5-HTT À/À mice showed robust phenotypic abnormalities as compared to +/+ littermates, suggestive of increased anxiety-like behavior and inhibited exploratory locomotion. The selective 5-HT 1A receptor antagonist, WAY 100635 (0.05-0.3 mg/kg), produced a significant anxiolytic-like effect in the elevated plus maze in 5-HTT À/À mice, but not +/+ controls. The present findings demonstrate abnormal behavioral phenotypes in 5-HTT null mutant mice in tests for anxiety-like and exploratory behavior, and suggest a role for the 5-HT 1A receptor in mediating these abnormalities. 5-HTT null mutant mice provide a model to investigate the role of the 5-HTT in mood and anxiety disorders.
INTRODUCTION
A wealth of research implicates the brain serotonin system in the pathophysiology and treatment of mood and anxiety disorders (Charney et al, 1999) . The cell membrane serotonin transporter (5-HTT) acts as a critical regulator of serotonin signaling, via reuptake of serotonin from the perisynaptic and synaptic space (Blakely et al, 1991; Ramamoorthy et al, 1993) . Drugs which block 5-HTT activity act as antidepressants and anxiolytics (Ballenger, 1999; Stein and Berk, 2000; Kugaya et al, 2003) . Moreover, there is evidence that abnormalities in 5-HTT expression or function may contribute to the etiology of depression and anxiety disorders. In drug-free patients, studies of postmortem brain tissue, living brain, and platelets have found evidence of reduced 5-HTT binding in affective disorders (eg Briley et al, 1980; Nemeroff et al, 1994; Malison et al, 1998; Willeit et al, 2000; Arango et al, 2002) . There is also growing evidence that genetic variation in 5-HTT function may affect relative risk for emotional disorders. A common 44-base pair insertion/deletion functional polymorphism in the HTT (SLC6A4) determines levels of 5-HTT mRNA and binding sites, as well as serotonin reuptake (Lesch et al, 1996; Little et al, 1998; Greenberg et al, 1999) . Individuals harboring the low-activity HTT variant show higher trait anxiety/dysphoria, and great neuronal responses to fear, and are at increased risk for depression than those without this variant (Lesch et al, 1996; Mazzanti et al, 1998; Greenberg et al, 2000; Murphy et al, 2001; Hariri et al, 2002; Caspi et al, 2003) .
To further study the role of the 5-HTT in anxiety, we generated mutant mice in which the 5-HTT gene (htt, slc6a4) has been constitutively inactivated . Previous studies have confirmed that 5-HTT null mutant mice exhibit marked alterations in serotonergic homeostasis. Thus, 5-HTT binding sites in brain are absent in 5-HTT homozygous (À/À) null mutant mice and are reduced 50% in 5-HTT heterozygous (+/À) mutant mice . 5-HTT À/À mice exhibit an absence of high-affinity, Na-and Cl-dependent, 3H-5-HT uptake in cortical or brainstem synaptosomes, while gross brain serotonin concentrations are decreased to 20-40% of normal levels in these mice Tjurmina et al, 2002) . Loss of 5-HTT-mediated reuptake leads to prolonged clearance of serotonin in 5-HTT À/À and 5-HTT +/À mice, as measured in the hippocampus using in vivo chronoamperometry (Montanez et al, 2003) . As a result, basal extracellular serotonin is increased nine-fold in 5-HTT À/À mice and five-fold in 5-HTT +/À mice, as measured by zero net flux microdialysis in the striatum (Mathews et al, 2000) . As a compensatory response to chronically elevated levels of extracellular serotonin, 5-HTT null mutant mice exhibit decreases in 5-HT receptor expression and function (Rioux et al, 1999; Fabre et al, 2000; Mannoury la Cour et al, 2001; Sora et al, 2001; Li et al, 2000 Li et al, , 2003 Holmes et al, 2002a) . Despite downregulation and desensitization of 5-HT 1A autoreceptors, basal serotonin dorsal raphe neuron firing is reduced in 5-HTT null mutant mice, indicating a lack of adaptation to increased extracellular serotonin . 5-HTT null mutants also show relatively minor compensatory changes in other monoamine systems. Levels of norepinephrine, dopamine and their metabolites in 5-HTT null mutant mice are similar to those found in +/+ controls, as is the number of norepinephrine or dopamine transporter binding sites Zhou et al, 2002) . How prolonged changes in serotonergic homeostasis impact anxiety-related behaviors in 5-HTT null mutant mice is the subject of the present investigation.
Behavioral phenotyping in our laboratory has shown that 5-HTT null mutant mice are normal on a range of measures of gross neurological and sensory ability, but exhibit reduced conspecific aggression, reduced home cage locomotor activity, abnormal depression-related behaviors, and altered responses to antidepressants (Holmes et al, 2002a, b) . In addition, 5-HTT null mutant mice have been found to show abnormalities in reward-related and locomotor responses to psychostimulants Uhl et al, 2002) , analgesic responses (Vogel et al, 2003) , and REM sleep (Wisor et al, 2003) . In the present study, 5-HTT null mutant mice were characterized for anxiety-related behaviors using a battery of tests (ie elevated plus maze, light2dark exploration test, emergence test, and open field test), as previously described (Holmes et al, 2003) . Neuropharmacological studies of 5-HT 1A receptor compounds and phenotyping of 5-HT 1A receptor null mutation mice gene implicate this receptor in neural circuits underlying emotion (Griebel, 1995; Griebel et al, 1999 Griebel et al, , 2000 Olivier et al, 1999; Canto-de-Souza et al, 2002; Gross et al, 2002; Nunes-de-Souza et al, 2002) . Furthermore, we have recently found that a functional polymorphism in the transcriptional control region of the human 5-HT 1A gene is associated with anxiety traits (Strobel et al, 2003) . Thus, in order to study whether abnormal signaling at the 5-HT 1A receptor may contribute to an anxiety-related phenotype in 5-HTT null mutant mice, we assessed the behavioral consequences of pharmacological blockade of the 5-HT 1A receptor in the elevated plus-maze test for anxiety-like behavior.
MATERIALS AND METHODS

Subjects
Serotonin transporter (5-HTT) null mutant mice were generated as previously described . Briefly, 3 0 and 5 0 DNA fragments encompassing exon 2 of the htt and with an overall length of 7.5 kb were inserted into the pPNT-neo replacement targeting vector, containing a neo and TK cassette under the control of the PGK promoter. A 1.1 kb BamHI/HindIII fragment was replaced by the 1.8 kb PGK neomycin-polyA expression cassette. In all, 129 R1 embryonic stem cells were cultured, transfected, and subjected to double selection. DNA was digested with Asp718 and hybridized with a 3 0 probe that recognized a htt sequence external to the construct. In addition, recombinant embryonic stem cell clones were identified by Southern blot analysis, with the use of a 5 0 HindIII/BamHI probe to confirm accurate gene targeting. Embryonic stem cell clones were microinjected in C57BL/6J blastocysts to obtain chimeric progeny. Chimeric males were mated to C57BL/ 6J female mice and pups genotyped by Southern blot analysis of tail biopsies to confirm germline transmission. For behavioral experiments, the 5-HTT mutation was backcrossed into a C57BL/6J genetic background for eight generations. 5-HTT mutant mice and +/+ littermate controls were derived from 5-HTT +/À Â 5-HTT +/À matings, and are viable, and reproduce and develop normally.
Behavioral Testing
Behavioral testing was conducted on two separate cohorts of mutant mice and their littermate controls, all bred and raised at the National Institute of Mental Health (Bethesda, MD, USA). At weaning, mice were group housed with samesex littermates, in a temperature-and humidity-controlled vivarium, under a 12 h light/dark cycle (lights on 0600 h). Cohort 1 was assessed on an anxiety-related test battery and consisted of 13 5-HTT À/À, 15 5-HTT +/À, and 15 +/+ female mice, and 13 5-HTT À/À, 18 5-HTT +/À, and 13 +/+ male mice. Male and female mice were tested separately. Over a 4-week period, mice were tested on the emergence test, light2dark exploration test, elevated plus maze, and open field test, in that order. To control for the potential effects of prior test experience on anxiety-like behavior (Holmes and Rodgers, 1998 ), each mouse was tested in each behavioral test. In cases of a failure of the test equipment or poor physical condition of the animal on the day of testing, data were removed from the analysis. Cohort 2 was tested for the effects of WAY 100635 in the elevated plus maze and consisted of 43 5-HTT À/À, 45 5-HTT +/À, and 45 +/+ female mice. For both cohorts, subjects were 3-7 months of age. To ensure that experimenters remained blind to genotype, subjects were only identified by individual ear tag numbers until the completion testing. Testing was conducted during the light phase of the light/ dark cycle (0600-1800 h). Mice were transported to the test room at least 1 h prior to testing to allow for acclimation. The test equipment was cleaned with a weak ethanol solution and dried between subjects. All experimental procedures were approved by the National Institute of Mental Health Animal Care and Use Committee, and followed the National Institute of Health guidelines outlined in 'Using Animals in Intramural Research.'
Elevated Plus Maze
The elevated plus maze was conducted as previously described (Lister, 1987; File, 2001; Bale et al, 2002; Holmes et al, 2002b Holmes et al, , 2003 
Light2Dark Exploration Test
The light2dark exploration test was conducted as previously described (Crawley, 1981; Mathis et al, 1994; Holmes et al, 2002b Holmes et al, , 2003 . The apparatus consisted of a polypropylene cage (44 Â 21 Â 21 cm 3 ) separated into two compartments by a partition, which had a small opening (12 Â 5 cm 2 ) at floor level. The larger compartment (28 cm long) was open-topped, transparent, and very brightly illuminated by a desk lamp (1000 lx). The smaller compartment (14 cm long) was close-topped and painted black. Mice were individually placed in the center of the light compartment, facing away from the partition, and allowed to freely explore the apparatus for 10 min. The number of light2dark transitions between the two compartments, and the total time spent in the dark compartment, were automatically recorded via photocells located at the opening between compartments, connected to a custom-built data analyzer (Bruce Smith and colleagues, Research Services Branch, National Institute of Mental Health, Bethesda, MD, USA).
Emergence Test
The emergence test was conducted as previously described (Takahashi et al, 1989; Smith et al, 1998; Holmes et al, 2003) . Mice were first placed inside the shelter, with the exit closed, for a 5 min habituation period. After the habituation period, the exit was opened to allow the mouse to leave the shelter and explore the open field for 5 min. The latency to emerge from the shelter, time spent out of the shelter and shelter2open field transitions were recorded by an experienced observer using behavioral scoring software (Hindsight, Scientific Programming Services, Wokingham, UK).
Open Field Test
The open field test was conducted as previously described (Mathis et al, 1994; Holmes et al, 2001 Holmes et al, , 2003 Miyakawa et al, 2001 ). The open field was a square arena ( 
Effects Of Way 100635 In The Elevated Plus Maze
Experimentally naïve female mice were tested for the effects of the 5-HT 1A receptor antagonist, WAY 100635, in the elevated plus maze. Mice were injected with either vehicle or 0.05, 0.1, or 0.3 mg/kg WAY 100635, and tested on the elevated plus maze 30 min later using the same procedure as described above.
(Wyeth Research, Monmouth Junction, NJ, USA) was freshly dissolved in distilled water, which also served as an inert vehicle. Vehicle or 0.05, 0.1, or 0.3 mg/kg WAY 100635 was injected subcutaneously 30 min prior to testing, in a volume of 10 mg/kg body weight. Doses of WAY 100635 were chosen on the basis of pilot studies in 5-HTT null mutant mice and +/+ controls and previous reports of the anxiety-related effects of this drug in mice (Collinson and Dawson, 1997; Cao and Rodgers, 1997b; Griebel et al, 1999 Griebel et al, , 2000 .
Statistical Analyses
Statistical analyses were conducted using StatView software (SAS Institute Inc., Cary, NC, USA). Males and females were tested as separate groups and, therefore, not statistically compared. The effect of genotype was analyzed using analysis of variance (ANOVA). Open field horizontal activity was analyzed by two-factor ANOVA (genotype Â time), with repeated measures for the factor of time, and Newman-Keuls post hoc tests where appropriate. For drug studies, the effects of genotype and WAY 100635 were analyzed using two-factor ANOVA (drug Â genotype), and Newman-Keuls post hoc tests where appropriate. Statistical significance was set at po0.05.
RESULTS
Elevated Plus Maze
Elevated plus-maze results are presented in Figure 1 . 
Light2Dark Exploration Test
Light2dark exploration test results are presented in Figure  2a and (F(2,39) ¼ 5.56, po0.01). Newman-Keuls post hoc tests showed that vertical activity (po0.01) and percent center time (po0.01) were both significantly lower in 5-HTT À/À mice than +/+ littermates, while vertical activity was also significantly lower in male 5-HTT +/À mice than +/+ littermates (po0.01).
Effects Of Way 100635 In The Elevated Plus Maze
The effects of the 5-HT 1A receptor antagonist WAY 100635 on elevated plus-maze behavior in female mice are shown in (F(6,121) ¼ 0.96, p ¼ 0.46), on rears. Newman-Keuls post hoc tests showed that WAY 100635 significantly decreased rears in 5-HTT +/À mice at 0.3 mg/kg (po0.05), but had no effect in 5-HTT À/À mice or +/+ littermates at any dose tested (all p40.05). In addition, rears were significantly lower in 5-HTT À/À mice than +/+ littermates at all doses tested (all po0.05).
In confirmation of the genotype-specific anxiolytic-like effects of WAY 100635 on elevated plus-maze behavior, a separate batch of (male) 
DISCUSSION
The present findings show that targeted disruption of the serotonin transporter (5-HTT) gene (htt,slc6a4) leads to abnormalities in anxiety-like behavior and exploratory locomotion in mice. Abnormal behavioral phenotypes in 5-HTT null mutant mice were confirmed using four separate tests for anxiety-like behavior and were evident in both males and females.
Blockade of the 5-HT 1A receptor, via acute treatment with the highly selective antagonist, WAY 100635, produced anxiolytic-like effects in 5-HTT À/À mice, but not +/+ controls, suggesting a role for the 5-HT 1A receptor in mediating anxiety-related abnormalities in 5-HTT null mutant mice.
5-HTT null mutant mice demonstrated robust phenotypic abnormalities in the four tasks employed in our anxietyrelated behavioral test battery. In the elevated plus maze, 5-HTT À/À mice showed a greater avoidance of the aversive open arms than +/+ littermate controls, consistent with increased anxiety-like behavior in this test. Abnormal behavior was also found in 5-HTT À/À mice in two tests that measure responses to light/dark conflict. In the light2dark exploration test, female 5-HTT À/À mice showed fewer transitions between light and dark compartments and spent more of the test session in the dark compartment than their +/+ littermates. Male 5-HTT À/À mice also showed relatively few intercompartmental transitions, but did not show a heightened preference for the dark compartment. The absence of an anxiety-like bias for the dark compartment in male 5-HTT À/À mice reflects the fact that B40% of these mice displayed complete behavioral inhibition when placed in the light compartment at the start of the test session, which skewed scores to show a false light compartment preference. The emergence test is less likely to be confounded by behavioral inhibition caused by precipitous exposure to an aversive light area, because mice are initially placed within a protected, darkened shelter prior to the light/dark conflict phase. In the emergence test, both male and female 5-HTT À/À mice showed reduced exploration and an overall avoidance of a brightly illuminated arena, as compared to +/+ littermates.
In exploration-based tests for anxiety-like behavior, such as the light2dark exploration or emergence tests, it can be difficult to dissociate a strong anxiety-like phenotype from an impairment in exploratory locomotion per se, as both can manifest as an inhibition of exploratory locomotion (Blanchard et al, 1990; Crawley, 2000; File, 2001; Holmes, 2001; McNaughton and Gray, 2000) . In this context, 5-HTT À/À mice were no different from +/+ controls on independent measures of locomotor activity (ie entries and rears in the protected closed arms) in the elevated plus maze, under baseline conditions. This profile is consistent with a selective increase in anxiety-like behavior, rather than a more general deficit in locomotor activity, in 5-HTT À/À mice in this test. However, importantly, profiles in other tests were more equivocal. For example, the behavior of 5-HTT À/À mice in the open field would be consistent with either an increase in anxiety-like behavior (ie reduced center time) or deficient locomotor exploration (ie reduced horizontal and vertical activities). Moreover, we have previously found that 5-HTT À/À mice show lower levels of locomotor activity than their +/+ littermates in the home cage (Holmes et al, 2002a) . Therefore, the most likely interpretation for the present results is that targeted disruption of the 5-HTT has adverse pleiotropic consequences for both anxiety-like behavior and exploratory locomotion. In order to further understand the precise nature of the behavioral abnormalities in 5-HTT null mutant mice, it will be of critical importance to assess these mice on behavioral tasks that are not contingent upon normal exploratory locomotion (eg Vogel conflict test, fearpotentiated startle, fear-conditioned freezing).
Interestingly, 5-HTT +/À mice were similar to +/+ controls on measures of anxiety-like behavior, with only minor exceptions. Abnormalities in exploratory locomotion in 5-HTT +/À mice were limited to specific measures under baseline conditions (ie lower open field vertical activity), but extended to additional measures under putatively more stressful test conditions (ie lower open field horizontal activity following saline injection). We have previously found that 5-HTT +/À mice exhibit reduced aggressive behavior that is limited to specific measures and test conditions (Holmes et al, 2002a) . By contrast, 5-HTT +/À mice exhibit clear perturbations in serotonergic homeostasis that are intermediate between profiles evident in 5-HTT À/À mice and +/+ controls, including elevated extracellular serotonin, decreased dorsal raphe firing, and reduced 5-HT 1A receptor expression and function Gobbi et al, 2001; Mathews et al, 2000; Montanez et al, 2003) . Thus, the present findings suggest that serotonergic dysfunction in 5-HTT +/À mice may manifest as behavioral abnormalities only under challenging environmental conditions.
The neural mechanisms underlying abnormal anxiety-like behavior and exploratory locomotion may relate to alterations in serotonergic neurotransmission in 5-HTT null mutant mice. Studies using either in vivo microdialysis in striatum (Mathews et al, 2000) or in vivo chronoamperometry in the hippocampus (Montanez et al, 2003) have shown that 5-HTT null mutants exhibit an absence of transporter-mediated clearance and a clear increase in basal levels of extracellular serotonin. Increased extracellular serotonin would be expected to cause excess activity at postsynaptic serotonin receptors which, in turn, could underlie increased anxiety-like behaviors in 5-HTT À/À mice (Iversen, 1984; Graeff et al, 1996) . To test this hypothesis, we examined the effects of pharmacological blockade of serotonin receptors on anxiety-like behaviors in 5-HTT null mutants. The initial focus of these studies was the 5-HT 1A receptor subtype, using the highly selective 5-HT 1A receptor antagonist, WAY 100635 (Forster et al, 1995; Fletcher et al, 1996) . Converging lines of evidence implicate the 5-HT 1A receptor subtype in the mediation of both clinical anxiety (Lesch, 1991; Strobel et al, 2003; Rickels and Rynn, 2002) and anxiety-like behavior in rodents (Griebel, 1995; Canto-de-Souza et al, 2002; Griebel et al, 1999 Griebel et al, , 2000 Olivier et al, 1999; Gross et al, 2002; Nunes-de-Souza et al, 2002) . For example, studies have shown that activation of postsynaptic 5-HT 1A receptors in the forebrain regions, including the septum and hippocampus, leads to WAY 100635-reversible increases in anxiety-like behavior in various tasks (Andrews et al, 1994; File et al, 1996 File et al, , 2000 ; but see Menard and Treit, 1998; Cervo et al, 2000) . Furthermore, administration of WAY 100635 alone into the hippocampus has anxiolytic-like effects in the mouseelevated plus maze under specific test conditions (Nunesde-Souza et al, 2002) .
In the present study, acute, systemic treatment with WAY 100635 led to a complete reversal of the anxiety-like phenotype in 5-HTT À/À mice in the elevated plus maze. In replication of our baseline study, vehicle-treated 5-HTT À/À mice showed higher levels of anxiety-like behavior than vehicle-treated +/+ controls, as demonstrated by significantly lower percent open arm time and a trend for lower percent open entries. In contrast, 5-HTT À/À mice treated with 0.05 and 0.3 mg/kg WAY 100635 were no different from +/+ controls and actually showed a relatively anxiolytic-like profile following treatment with 0.1 mg/kg WAY 100635. These doses of WAY 100635 had no significant effect on plus-maze anxiety-like behavior in +/+ controls either in this experiment or in our pilot studies. At the doses presently tested, systemic administration of WAY 100635 and other selective antagonists, such as mPPI, has been found to exert anxiolytic-like effects in the various rodent tasks, including the elevated plus maze, in some studies (eg Cao and Rodgers, 1997a, b; Griebel et al, 1999 Griebel et al, , 2000 , but not others (eg File et al, 1996; Collinson and Dawson, 1997; Mendoza et al, 1999; Hata et al, 2001 ; for reviews see Griebel, 1995; Cao and Rodgers, 1997a, b; Griebel et al, 1999) . One possible reason for this variability is that the effects of 5-HT 1A receptor antagonists will depend upon basal serotonergic tone and baseline anxietylike behavior evoked in a given test situation, which will vary somewhat across laboratories (Rodgers and Cao, 1999) . The present finding that WAY 100635 failed to reduce anxiety-like behavior in +/+, but had marked anxiolyticlike effects in 5-HTT À/À mice, would support this argument, given the increased extracellular serotonin the latter (Mathews et al, 2000; Montanez et al, 2003) .
Motoric disturbances in the mouse-elevated plus maze have been found following treatment with WAY 100635, although usually at higher doses than those presently tested (Rodgers and Cole, 1994; Cao and Rodgers, 1997b; Griebel et al, 1999 Griebel et al, , 2000 . At the highest dose tested (0.3 mg/kg), WAY 100635 reduced closed entries in both 5-HTT À/À mice and +/+ controls and rears in 5-HTT +/À mice. Therefore, this dose of WAY 100635 appeared to produce nonspecific motoric effects. There was a reduction in closed arm entries, but not rears, in 5-HTT À/À mice treated with 0.1 mg/kg WAY 100635. Given the absence of any behavioral effect of this dose in 5-HTT +/À mice or +/+ controls, this effect could reflect the fact that 5-HTT À/À mice showed very high (B70%) percent open arm time and percent open entries and, as such, had relatively little opportunity to explore the closed arms.
In our pharmacological experiment, 5-HTT À/À mice exhibited a general decrease in closed arm entries and rears relative to +/+ controls. This contrasts with the normal locomotor activity observed in 5-HTT À/À mice in the elevated plus maze under baseline (ie no injection) conditions. Previous studies have found that prior exposure to stressors causes a general suppression of exploratory activity in various rodents tests for anxiety-like behavior (Kennett et al, 1987; Cheeta et al, 2000; Padovan and Guimaraes, 2000) . In addition, we have previously found that 5-HTT À/À mice exhibit exaggerated neuroendocrine (plasma adrenocorticotropin) responses to injection stress, as compared to +/+ controls . Thus, one possible explanation for reduced closed arm entries and rears in 5-HTT À/À mice in the pharmacological, but not baseline, experiment is that there are genotype differences in the stress response to injection. However, in the absence of further studies that directly address this question, this profile is taken as further evidence of abnormal exploratory locomotion in 5-HTT null mutant mice. Interestingly, while WAY 100635 reversed anxiety-related measures of open arm exploration in 5-HTT À/À mice, genotype differences in closed arm entries and rears were not normalized by the drug. These findings suggest that the 5-HT 1A receptor plays a major role in mediating increased anxiety-like behavior, but not abnormal exploratory locomotion, in 5-HTT null mutant mice.
The ability of WAY 100635 to produce anxiolytic-like effects in 5-HTT À/À mice could be taken as evidence that abnormal anxiety-like behaviors in these mice are driven by increased extracellular serotonin acting at postsynaptic 5-HT 1A receptors. It should be noted that, while the number of somatodendritic 5-HT 1A autoreceptor in raphe neurons is reduced 450% in 5-HTT À/À mice, postsynaptic 5-HT 1A receptor binding is only partially reduced in the hypothalamus, septum, and amygdala, and is not reduced whatsoever in the frontal cortex or hippocampus (Fabre et al, 2000; Li et al, 1999 Li et al, , 2000 Mannoury la Cour et al, 2001) . Thus, although postsynaptic 5-HT 1A receptors are downregulated in some forebrain regions, reduced clearance and increased extracellular concentrations of serotonin in 5-HTT null mutant mice could still cause excess activation of postsynaptic 5-HT 1A receptors, and somehow contribute to the increased anxiety-like behavior and its reversal by WAY 100635 in these mice.
However, there are a number of important caveats to this model. Firstly, 5-HT 1A receptors are not only expressed as postsynaptic receptors in forebrain regions, but also act as somatodendritic autoreceptors in the dorsal and median raphe nuclei. Systemic administration of WAY 100635 will antagonize both populations of 5-HT 1A receptors. Gobbi et al (2001) have recently shown that systemic WAY 100635 causes a marked increase in serotonin dorsal raphe firing in 5-HTT À/À mice, at a dose that reduced anxiety-like behavior in the present study. Therefore, the net effect of WAY 100635 on serotonergic neurotransmission in 5-HTT À/À mice may be more complex than originally anticipated. For example, increased serotonin neuronal firing induced by WAY 100635 in 5-HTT null mutants would be predicted to (1) increase activity at other serotonin receptors implicated in anxiety (eg 5-HT 2C receptor; Martin et al, 1998) and, (2) alter activity at other neurotransmitter systems that are intimately associated with serotonin and the mediation of anxiety, such as norepinephrine (Szabo and Blier, 2001) , corticotropin-releasing factor , and substance P (Santarelli et al, 2001) .
Secondly, analogous to the phenotypic profile of 5-HTT null mutant mice, chronic treatment with serotonin transporter uptake blockers leads to somewhat increased extracellular serotonin (Frazer and Daws, 1998 ) and a partial desensitization of 5-HT 1A receptors (Pineyro and Blier, 1999 ); yet these drugs are clinically effective anxiolytics. Furthermore, genetic disruption (antagonism) of the 5-HT 1A receptor causes increased anxiety-like behavior in mice, not the reverse (Heisler et al, 1998; Parks et al, 1998; Ramboz et al, 1998) . These findings could lead one to predict that increased serotonergic neurotransmission acting through the 5-HT 1A receptor would reduce anxiety, rather than cause the increase in anxiety-like behavior seen in 5-HTT À/À mice. However, the mechanisms underlying the anxiolytic effects of serotonin transporter uptake blockers are incompletely understood, while the basis of the anxiety-like phenotype in the 5-HT 1A receptor null mutant mice also appears to be more complex than initially thought. For example, Gross et al (2002) have recently found that inactivation of the 5-HT 1A receptor gene in adult mice does not affect anxiety-like behavior. Instead, their findings suggest that the anxiety-like phenotype in the 5-HT 1A receptor null mutant mice is caused by the absence of the receptor during a critical period of postnatal development. This important finding adds to a growing literature, demonstrating a central role for serotonin in the neurodevelopment of systems mediating emotion (Meaney et al, 1994; Levitt et al, 1997) . The potential for neurodevelopment abnormalities affecting anxiety-like behavior in 5-HTT null mutant mice should not be underemphasized (Lesch and Mossner, 1998; Persico et al, 2001) . Indeed, given the absence of the 5-HTT throughout ontogeny, 5-HTT null mutant mice provide a research tool for studying the potential long-term behavioral consequences of exposure to serotonin reuptake inhibitors during neurodevelopment.
5-HTT null mutant mice may also provide a model to study how genetic variation in the 5-HTT modulates human emotional responses. The short allele of a common polymorphism in the promoter region of the HTT causes reduced expression of the 5-HTT Lesch et al, 1996; Little et al, 1998; Greenberg et al, 1999) . Consistent with the finding that the genetic inactivation of the mouse 5-HTT gene leads to increased anxiety-like behavior, the low-expressing human 5-HTT polymorphism is associated with heightened trait anxiety/dysphoria, increased stress-reactive depression and exaggerated neural responses to fear (Lesch et al, 1996; Mazzanti et al, 1998; Greenberg et al, 2000; Hariri et al, 2002; Caspi et al, 2003) . Our findings demonstrating that treatment with a 5-HT 1A receptor antagonist can normalize anxiety-like behavior in 5-HTT À/À mice, may suggest novel pharmacogenomic approaches to treating anxiety disorders associated with the low-expressing HTT variant.
In summary, the present findings show that genetic deletion of the serotonin transporter produced abnormalities in anxiety-like behavior across a battery of behavioral tests, along with reduced exploratory activity. Increased anxiety-like behavior, but not reduced exploratory locomotion, in 5-HTT À/À mice was reversed by acute treatment with a 5-HT 1A receptor antagonist. The anxiety-like phenotype in 5-HTT À/À mice adds to an emerging picture of abnormalities in 5-HTT null mutants across a range of behavioral, neuroendocrine, and physiological parameters associated with emotional disorders, including abnormal responses to stress Tjurmina et al, 2002) , increased sensitivity to drugs of abuse (Uhl et al, 2002) , impaired gastrointestinal motility (Chen et al, 2001) , and disturbed REM sleep (Wisor et al, 2003) . 5-HTT null mutant mice provide a model to investigate the role of the 5-HTT in mood and anxiety disorders.
